Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

5Total
P 1 (1)
P 2 (4)

Trial Status

Active Not Recruiting2
Unknown1
Recruiting1
Not Yet Recruiting1

Clinical Trials (5)

Showing 5 of 5 trials
NCT05969860Phase 2Recruiting

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer

NCT04491942Phase 1Active Not Recruiting

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

NCT05521997Phase 2Not Yet RecruitingPrimary

Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer

NCT06238635Phase 2Active Not Recruiting

Dostarlimab and Cobolimab in Advanced Cervical Cancer

NCT04635956Phase 2Unknown

Camrelizumab Combined With Chemotherapy for Recurrent or Advanced Cervical Neuroendocrine Carcinomas

Showing all 5 trials

Research Network

Activity Timeline